<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373662">
  <stage>Registered</stage>
  <submitdate>17/09/2017</submitdate>
  <approvaldate>25/09/2017</approvaldate>
  <actrnumber>ACTRN12617001346369</actrnumber>
  <trial_identification>
    <studytitle>Single dose study of febuxostat (80 mg) in healthy subjects. </studytitle>
    <scientifictitle>The pharmacokinetics and pharmacodynamics of a single dose of febuxostat (80 mg) in healthy subjects.  </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None. </secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic gout</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Healthy subjects will be  orally administered a single dose of febuxostat (80 mg).  Urine (total catch) and blood samples will be collected at baseline (before administrating the dose) and for 102 hours post dose administration. 
No adherence assessment is required in this single dose study. 
</interventions>
    <comparator>No control group.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Examine the pharmacokinetics ([Cmax], time to reach Cmax [tmax], apparent clearance, apparent volume of distribution and half-life) of a single dose of febuxostat (80 mg) in healthy subjects. Blood samples will be collected immediately pre- dose and at the following times after dose administration: 1, 3, 6, 9, 24, 31, 48, 72, 96 and 102 hours. Plasma febuxostat will be determined by a HPLC method. </outcome>
      <timepoint>The plasma concentrations of febuxostat will be determined  pre-dose and at the following times after dose administration: 1, 3, 6, 9, 24, 31, 48, 72, 96 and 102 hours. </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Examine the change in serum urate over 102 hours following the administration of a single dose of febuxostat (80 mg) in healthy subjects.  Blood samples will be collected immediately pre- dose and at the following times after dose administration: 1, 3, 6, 9, 24, 31, 48, 72, 96 and 102 hours. Serum urate will be determined by the uricase method (St Vincent's pathology, Sydpath). </outcome>
      <timepoint>The concentrations of serum urate will be measured immediately pre- dose and at the following times after dose administration: 1, 3, 6, 9, 24, 31, 48, 72, 96 and 102 hours. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Investigate the effect of a single dose of febuxostat (80 mg) on the renal handling of urate (fractional clearance of urate).  Uric acid and creatinine will be measured by the Uricase method (Sydpath) and the Jaffe reaction (Sydpath), respectively. Blood and urine samples will be collected before administering a single dose of febxuostat (80 mg) and for 102 hour post dose administration. The serum and urinary urate and creatinine will be used to calculate the fractional clearance of urate pre and post dose administration. </outcome>
      <timepoint>Blood samples will be collected immediately pre- dose and at the following times after dose administration: 1, 3, 6, 9, 24, 31, 48, 72, 96 and 102 hours. Urine (total catch) will be collected 24 hour pre dose and at the following times after dose administration:  0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-36, 36-48, 72, 96 and 101-102. hours. Serum and urinary urate and creatinine concentrations will be measured at baseline and over 102 hours following the administration of a single dose of febuxostat (80 mg). 
</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy subjects</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Subject  with a history of any chronic disease. </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Not applicable. </concealment>
    <sequence>Nil. </sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Nil. </designfeatures>
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods>A sample size of 10 participants was considered sufficient to explore the time course of the hypouricaemic effects of a single dose of febuxostat (80 mg) and the effect of a single dose of febuxostat (80 mg) on the renal handling of urate. 
Febuxostat pharmacokinetic parameters (maximum plasma concentration [Cmax], time to reach Cmax [tmax], apparent clearance, apparent volume of distribution and half-life) will be determined. In addition, the concentration-time profile of serum urate concentrations over a period of 5 days after the administration of a single dose of febuxostat (80 mg) will be defined.  Urate excretion rate will be estimated before and after febuxostat administration. Serum and urinary urate and ceratinine will be used to calculate the fractional clearance of urate (FCU). The effect of a single dose of febuxostat on the renal handling of urate will be explored and reported. The relationship between the plasma concentrations of febuxostat and response (in terms of serum uarte lowering) will be fitted using modelling techniques.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>5/07/2016</actualstartdate>
    <anticipatedenddate>11/12/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <currentsamplesize>2</currentsamplesize>
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>18/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>St Vincent's Hospital (Darlinghurst) - Darlinghurst</hospital>
    <postcode>2010 - Darlinghurst</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St Vincent's Hospital, Sydney</primarysponsorname>
    <primarysponsoraddress>St Vincent's Hospital, 390 Victoria St, Darlinghurst, Australia, NSW 2010.</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Clinical Pharmacology Lexy Davies Trust Fund</fundingname>
      <fundingaddress>St Vincent's Hospital, 390 Victoria St, Darlinghurst, Australia, NSW 2010.</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Healthy subjects will be administered a single dose of febuxostat (80 mg) to examine the the pharmacokinetic and pharmacodynamic profiles of febuxostat following the administration of a single dose (80 mg). This study will also investigate the effect of a single dose of febuxostat (80 mg) on the renal handling of urate. </summary>
    <trialwebsite>None. </trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital, Sydney</ethicname>
      <ethicaddress>390 Victoria Road, Darlinghurst, Australia, New South Wales 2010. </ethicaddress>
      <ethicapprovaldate>16/03/2016</ethicapprovaldate>
      <hrec>HREC/15/SVH/423</hrec>
      <ethicsubmitdate>17/12/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Richard Day</name>
      <address>Department of Clinical Pharmacology and Toxicology, Level 2 Xavier Building, St Vincent's Hospital, 390 Victoria St, Darlinghurst, Australia, NSW 2010.</address>
      <phone>+61, 2, 83822331</phone>
      <fax>+61, 2, 83822724</fax>
      <email>r.day@unsw.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Bishoy Kamel</name>
      <address>Department of Clinical Pharmacology and Toxicology, Level 2 Xavier Building, St Vincent's Hospital, 390 Victoria St, Darlinghurst, Australia, NSW 2010.</address>
      <phone>+61, 2, 83822051</phone>
      <fax>+61, 2, 83822724</fax>
      <email>b.kamel@unswalumni.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Richard Day</name>
      <address>Department of Clinical Pharmacology and Toxicology, Level 2 Xavier Building, St Vincent's Hospital, 390 Victoria St, Darlinghurst, Australia, NSW 2010.</address>
      <phone>+61, 2, 83822331</phone>
      <fax>+61, 2, 83822724</fax>
      <email>r.day@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Bishoy Kamel</name>
      <address>Department of Clinical Pharmacology and Toxicology, Level 2 Xavier Building, St Vincent's Hospital, 390 Victoria St, Darlinghurst, Australia, NSW 2010.</address>
      <phone>+61, 2, 83822051</phone>
      <fax>+61, 2, 83822724</fax>
      <email>b.kamel@unswalumni.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>